Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial
M Szarek, HD White, PH Steg, ODYSSEY OUTCOMES Committees and Investigators.
KEYWORDS
Alirocumab; acute coronary syndrome; total events